[Possible consequences on the follow up of type 2 diabetic patients of a recent modification of a glycosylated hemoglobin assay].
Glycated hemoglobin assay is considered as the gold standard for the follow-up of diabetic patients, and the assay must now be calibrated on the results of the method used in the DCCT study. It is considered as appropriate to intensify the therapy of type 2 diabetic patients when two consecutive values higher than 8% are observed. We present herein a case report illustrating the possible consequences on the follow up of type 2 diabetic patients of a recent significant modification, not reported elsewhere, aimed to eliminate a bias vs the DCCT method of a system, DCA 2000, largely used to determine HbA1c level in diabetic patients: before this modification, the DCA 2000 method underestimated the glycated hemoglobin level by 0.5% for a 8% value. Such is no more the case.